文献速递眼底病与葡萄膜炎

玻璃体内氟轻松乙酰缩酮植入剂治疗放射性视网膜病变:初步发现报告

INTRAVITREAL FLUOCINOLONE ACETONIDE IMPLANT FOR RADIATION RETINOPATHY: Report of Preliminary Findings.
PubMed 文献 · Retina · 2023-01-01

回顾性分析7例葡萄膜黑色素瘤患者发生放射性视网膜病变相关黄斑囊样水肿,在接受抗血管内皮生长因子和/或类固醇注射后转为0.18 mg玻璃体内氟轻松乙酰缩酮植入剂。植入后最佳矫正视力与中心亚视野厚度保持稳定,注射次数减少,仅2例需额外植入一次。

要点

  • 0.18 mg玻璃体内氟轻松乙酰缩酮植入剂用于放射性视网膜病变相关黄斑囊样水肿。
  • 植入后最佳矫正视力与中心亚视野厚度保持稳定,平均中心亚视野厚度降低30 µm。
  • 平均随访12.1个月,玻璃体内注射次数减少,仅2例需额外植入一次。

核心结论

  • 玻璃体内氟轻松乙酰缩酮植入剂是放射性视网膜病变黄斑囊样水肿的有效治疗方法。
  • 类固醇缓慢释放可持续控制黄斑水肿,与视力稳定和注射负担降低相关。

研究设计与样本

  • 回顾性综述,纳入7例接受葡萄膜黑色素瘤治疗并发生放射性视网膜病变相关黄斑囊样水肿的患者。
  • 患者最初接受玻璃体内抗血管内皮生长因子和/或类固醇注射,后转为玻璃体内氟轻松乙酰缩酮植入剂。

主要发现

  • 植入后所有患者最佳矫正视力和中心亚视野厚度保持稳定。
  • 最佳矫正视力的方差从75.5 ETDRS字母(范围0-199字母)降至29.8(范围1.2-134)。
  • 植入前平均中心亚视野厚度为384 µm(范围165-641),植入后为354 µm(范围282-493),平均降低30 µm。
  • 玻璃体内注射次数(平均4.9次,范围2-10)在植入后减少,仅2例需额外植入一次氟轻松乙酰缩酮植入剂(平均0.29次,范围0-1)。
  • 平均随访12.1个月(范围0.9-18.5)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the efficacy of a 0.18 mg intravitreal fluocinolone acetonide (FA) implant (Yutiq, EyePoint Pharmaceuticals, Watertown, MA) as a treatment option for patients with radiation retinopathy-related cystoid macular edema. METHODS: A retrospective review of seven patients treated for uveal melanoma who developed radiation retinopathy-related cystoid macular edema. They were initially treated with intravitreal anti-vascular endothelial growth factor and/or steroid injections and then transitioned to intravitreal FA implant. Primary outcomes include best-corrected visual acuity, central subfield thickness, and number of additional injections. RESULTS: After FA implant insertion, best-corrected visual acuity and central subfield thickness remained stable in all patients. The variance in best-corrected visual acuity decreased from 75.5 ETDRS letters (range 0-199 letters) to 29.8 (range 1.2-134) after FA implant insertion. Mean central subfield thickness was 384 µ m (range 165-641) and 354 µ m (range 282-493) before and after FA implant insertion, resulting in a 30- µ m mean reduction. The number of intravitreal injections (average 4.9, range 2-10) decreased after intravitreal FA implant insertion with only two patients requiring one additional FA implant (average 0.29, range 0-1) over a mean of 12.1 months (range 0.9-18.5) follow-up. CONCLUSION: Intravitreal FA implant is an effective treatment for cystoid macular edema radiation retinopathy. The slow release of steroid allows for sustained control of macular edema, which correlated with stable visual acuity and decreased injection burden for patients.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Singaravelu J, Oakey ZB, Wrenn JM, et al. INTRAVITREAL FLUOCINOLONE ACETONIDE IMPLANT FOR RADIATION RETINOPATHY: Report of Preliminary Findings. Retina. 2023. PMID: 37027785. doi:10.1097/IAE.0000000000003808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。